Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
immunology
Biotech
AbbVie ends development of IL-1 asset in ulcerative colitis
AbbVie is ending development of an IL-1 asset as a monotherapy in ulcerative colitis after a phase 2 study revealed insufficient efficacy results.
Gabrielle Masson
Jul 31, 2025 12:32pm
Otsuka inks $613M deal for Swedish biotech's IL1RAP antibodies
Jul 16, 2025 1:37pm
Merck KGaA sheds light on failed portion of phase 2 lupus trial
Jun 12, 2025 9:41am
Sanofi pens $1.8B deal for 2 autoimmune, immunology bispecifics
Apr 17, 2025 8:51am
Sanofi hands over $600M upfront for Dren Bio's bispecific
Mar 20, 2025 5:58am
Merck KGaA fails lupus trial arm, plans further development
Mar 6, 2025 7:25am
